Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cliniphar's Enterprise Value is 円1,725 Mil.
Cliniphar's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円268 Mil. Therefore, Cliniphar's EV-to-FCF for today is 6.43.
The historical rank and industry rank for Cliniphar's EV-to-FCF or its related term are showing as below:
TSE:432A'
s EV-to-FCF Range Over the Past 10 Years
Min: 3.9 Med: 32.65 Max: 32.65
Current: 6.43
During the past 3 years, the highest EV-to-FCF of Cliniphar was 32.65. The lowest was 3.90. And the median was 32.65.
TSE:432A's EV-to-FCF is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 17.48
vs TSE:432A: 6.43
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cliniphar's share price for today is 円1450.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cliniphar's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円161.012.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cliniphar EV-to-FCF Related Terms
Cliniphar EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Cliniphar's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cliniphar EV-to-FCF Chart
Cliniphar Annual Data
Trend
Mar24
Mar25
Mar26
EV-to-FCF
0.00
0.00
3.90
Cliniphar Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
EV-to-FCF
0.00
0.00
0.00
3.90
Cliniphar EV-to-FCF Competitor Comparison
For the Pharmaceutical Retailers subindustry, Cliniphar's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cliniphar EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cliniphar's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cliniphar's EV-to-FCF falls into.
Cliniphar's current Enterprise Value is 円1,725 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cliniphar's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円268 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cliniphar (TSE:432A) has a EV-to-FCF of 6.43 as of Sep. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cliniphar and its competitors. This is 80% below median its historical median of 32.65. Over the past decade, Cliniphar's EV-to-FCF has ranged from 3.90 to 32.65.
Is Cliniphar's EV-to-FCF too high?
Cliniphar's current EV-to-FCF of 6.43 is 80% below median its 10-year median of 32.65. Over the past 10 years, this metric has ranged from a low of 3.90 to a high of 32.65. The Healthcare Providers & Services industry median EV-to-FCF is 17.48. Cliniphar's value of 6.43 is 63.2% below this industry median. Overall, Cliniphar has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Cliniphar's EV-to-FCF compare to competitors?
Cliniphar's EV-to-FCF of 6.43 can be compared against companies in the Healthcare Providers & Services industry. The industry median EV-to-FCF is 17.48. Cliniphar's value of 6.43 is 63.2% below this benchmark. Historically, Cliniphar's own EV-to-FCF has ranged from 3.90 to 32.65 over the past decade. While the company's 10-year median is 32.65 vs. the industry median of 17.48, Cliniphar has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.48, based on 420 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cliniphar's current EV-to-FCF of 6.43 is 63.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cliniphar and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cliniphar's current EV-to-FCF is 6.43, which is 80% below median its own 10-year median of 32.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cliniphar stock overvalued right now?
Cliniphar (TSE:432A) has a current EV-to-FCF of 6.43. The current EV-to-FCF is 6.43, which is 80% below median its 10-year median of 32.65 and 63.2% below the Healthcare Providers & Services industry median of 17.48. Cliniphar's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cliniphar (TSE:432A), the current EV-to-FCF is 6.43 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:432A has been successfully added to your 
